Fengkui Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fengkui Zhang has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Xin Zhao
Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
7 shared publicationsGuangxin Peng
Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
6 shared publicationsYuan Li
Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
6 shared publicationsHuihui Fan
Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
5 shared publicationsJianping Li
Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
5 shared publicationsLei Ye
Anemia Therapeutic Centre, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 shared publications
Latest Publications
- Open Access
- 25 September 2025
- Published by VM Media Group sp. z o.o in Endokrynologia Polska
Association between stress hyperglycemia ratio and mortality in critically ill patients across different glucose metabolic status and diabetes mellitus subtypes
Introduction: No study has specifically investigated the correlation between stress hyperglycemia ratio (SHR) and mortality in critically ill patients across different glucose metabolic status and diabetes mellitus (DM) subtypes. Material and methods: Analysis was conducted using the Medical Information Mart for Intensive Care-IV 2.2 database. Result: In this study, a total of 73,181 intensive care unit (ICU) patients were included, among whom 33,683 critically ill patients were included in the final analysis. Logistic model analysis revealed that the SHR was associated with elevated mortality rates in the ICU and in-hospital among patients with type 2 diabetes mellitus (T2DM) and those in the ICU with different glucose metabolism status, particularly in individuals with prediabetes mellitus (Pre-DM) and normal glucose regulation (NGR). In the Cox proportional hazards model, SHR was linked to an increased risk of one-year mortality, particularly among critically ill patients with Pre-DM. Mediation analysis revealed that the high SHR could account for 14.0% and 11.3% of the increased risk of ICU death and in-hospital mortality associated with DM, respectively. Conclusion: SHR is correlated with both short-term and long-term mortality in critically ill patients across various glucose metabolism status, particularly evident in those with NGR and Pre-DM. Moreover, SHR demonstrates an elevated risk of short-term and long-term mortality in critically ill patients with T2DM. Additionally, SHR plays a mediating role in the association between DM and mortality. Keywords: critically ill patients diabetes mellitus subtypes glucose metabolic status mortality stress hyperglycemia ratio
- 25 September 2025
- Published by VM Media Group sp. z o.o in Endokrynologia Polska
Open AccessAssociation between stress hyperglycemia ratio and mortality in critically ill patients across different glucose metabolic status and diabetes mellitus subtypes
Introduction: No study has specifically investigated the correlation between stress hyperglycemia ratio (SHR) and mortality in critically ill patients across different glucose metabolic status and diabetes mellitus (DM) subtypes. Material and methods: Analysis was conducted using the Medical Information Mart for Intensive Care-IV 2.2 database. Result: In this study, a total of 73,181 intensive care unit (ICU) patients were included, among whom 33,683 critically ill patients were included in the final analysis. Logistic model analysis revealed that the SHR was associated with elevated mortality rates in the ICU and in-hospital among patients with type 2 diabetes mellitus (T2DM) and those in the ICU with different glucose metabolism status, particularly in individuals with prediabetes mellitus (Pre-DM) and normal glucose regulation (NGR). In the Cox proportional hazards model, SHR was linked to an increased risk of one-year mortality, particularly among critically ill patients with Pre-DM. Mediation analysis revealed that the high SHR could account for 14.0% and 11.3% of the increased risk of ICU death and in-hospital mortality associated with DM, respectively. Conclusion: SHR is correlated with both short-term and long-term mortality in critically ill patients across various glucose metabolism status, particularly evident in those with NGR and Pre-DM. Moreover, SHR demonstrates an elevated risk of short-term and long-term mortality in critically ill patients with T2DM. Additionally, SHR plays a mediating role in the association between DM and mortality. Keywords: critically ill patients diabetes mellitus subtypes glucose metabolic status mortality stress hyperglycemia ratio
- 9 September 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (12) , 1-2
A case report of dyskeratosis congenita caused by a novel TERC mutation
- 9 September 2023
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (12) , 1-2
A case report of dyskeratosis congenita caused by a novel TERC mutation
- 15 July 2021
- Published by Wiley in American Journal of Hematology
- Vol. 96 (10) , 1232-1240
Comparison of Levitt's CO breath test and the 15N‐glycine labeling technique for measuring the lifespan of human red blood cells
The red blood cell (RBC) lifespan is an important physiological indicator of clear significance in clinical research, used for the differential diagnosis of various diseases such as anemia, compensatory phase hemolysis, and polycythemia. The 15N‐glycine labeling technique is the gold standard method for determining RBC lifespans. However, the usefulness of this technique in clinical settings is seriously hindered by the several weeks required to complete the analyses. Levitt's CO breath test is another reliable technique for determining RBC lifespans, with a simpler protocol giving much faster results, making it more useful in clinical applications. We compared the CO breath test and 15N‐glycine labeling technique for measuring the human RBC lifespan. We investigated human RBC lifespans where each subject undertook both the 15N‐glycine labeling technique and the CO breath test. The correlation between the results from these two methods was analyzed. Eight of the ten subjects successfully completed the study. The RBC lifespan values obtained by Levitt's CO breath test were lower than those obtained by the 15N‐glycine labeling technique. The RBC lifespan values determined from the 15N‐glycine labeling technique and the CO breath test were significantly correlated, with a Pearson correlation coefficient of R = 0.98 (p < 0.05), while the R2 of the linear regression equation was 0.96. The CO breath test exhibits as good performance as the 15N‐glycine labelling technique in distinguishing healthy subjects from subjects with hemolysis. The result suggests that the CO breath test is a reliable method for quickly determining human RBC lifespans in clinical applications.
- 15 July 2021
- Published by Wiley in American Journal of Hematology
- Vol. 96 (10) , 1232-1240
Comparison of Levitt's CO breath test and the 15N‐glycine labeling technique for measuring the lifespan of human red blood cells
The red blood cell (RBC) lifespan is an important physiological indicator of clear significance in clinical research, used for the differential diagnosis of various diseases such as anemia, compensatory phase hemolysis, and polycythemia. The 15N‐glycine labeling technique is the gold standard method for determining RBC lifespans. However, the usefulness of this technique in clinical settings is seriously hindered by the several weeks required to complete the analyses. Levitt's CO breath test is another reliable technique for determining RBC lifespans, with a simpler protocol giving much faster results, making it more useful in clinical applications. We compared the CO breath test and 15N‐glycine labeling technique for measuring the human RBC lifespan. We investigated human RBC lifespans where each subject undertook both the 15N‐glycine labeling technique and the CO breath test. The correlation between the results from these two methods was analyzed. Eight of the ten subjects successfully completed the study. The RBC lifespan values obtained by Levitt's CO breath test were lower than those obtained by the 15N‐glycine labeling technique. The RBC lifespan values determined from the 15N‐glycine labeling technique and the CO breath test were significantly correlated, with a Pearson correlation coefficient of R = 0.98 (p < 0.05), while the R2 of the linear regression equation was 0.96. The CO breath test exhibits as good performance as the 15N‐glycine labelling technique in distinguishing healthy subjects from subjects with hemolysis. The result suggests that the CO breath test is a reliable method for quickly determining human RBC lifespans in clinical applications.
- Open Access
- 14 February 2020
- Vol. 41 (2) , 112-116
[Clinical and laboratory analysis of 17 patients with γδT-cell large granular lymphocyte leukemia].
Objective: To compare the difference of the clinical and laboratory characteristics between γδ T-cell large granular lymphocyte leukemia (γδT-LGLL) and αβ T-cell large granular lymphocyte leukemia (αβT-LGLL) . Methods: The clinical and laboratory characteristics of 17 patients with γδT-LGLL and 91 patients with αβT-LGLL in the department of therapeutic center of anemia of enrolled in our hospital from January 2009 to January 2019 were retrospectively analyzed. Results: The median age of the 17 patients with γδT-LGLL was 54 years (range, 25-73 years) , the most common presenting symptom was anemia. In comparison with αβT-LGLL patients, splenomegaly was common (41% and 44%, respectively) , whereas hepatomegaly (12% and 5%, respectively) and lymphadenopathy (6% and 8%, respectively) were rare. The positive rates of antinuclear antibody (59% and 45%, respectively) were high, whereas the positive rates of rheumatoid factor (6% and 10%, respectively) were rare for both groups. There were no differences on peripheral blood counts between the two groups. However, γδT-LGLL patients were found to be predominantly expressed a CD4(-)/CD8(-) phenotype. Steroid therapy with prednisone was used alone as first-line therapy for 1 patient. Cyclosporin A (CsA) was used alone as first-line therapy for 3 patients. CsA in combination with steroids were administered in 13 patients. After 4 months treatment, 2 patients acquired complete response, 4 patients acquired partial response, the overall response was 35%. Conclusion: γδT-LGLL is a rare mature T-lymphocyte proliferative disease. Clinical and laboratory characteristics were quite similar for γδT-LGLL in compare with αβT-LGLL. γδT-LGLL predominantly expressed a CD4(-)/CD8(-) phenotype. The data presented here indicate the CsA is an effective option for the first-line treatment of γδT-LGLL.
- 14 February 2020
- Vol. 41 (2) , 112-116
Open Access[Clinical and laboratory analysis of 17 patients with γδT-cell large granular lymphocyte leukemia].
Objective: To compare the difference of the clinical and laboratory characteristics between γδ T-cell large granular lymphocyte leukemia (γδT-LGLL) and αβ T-cell large granular lymphocyte leukemia (αβT-LGLL) . Methods: The clinical and laboratory characteristics of 17 patients with γδT-LGLL and 91 patients with αβT-LGLL in the department of therapeutic center of anemia of enrolled in our hospital from January 2009 to January 2019 were retrospectively analyzed. Results: The median age of the 17 patients with γδT-LGLL was 54 years (range, 25-73 years) , the most common presenting symptom was anemia. In comparison with αβT-LGLL patients, splenomegaly was common (41% and 44%, respectively) , whereas hepatomegaly (12% and 5%, respectively) and lymphadenopathy (6% and 8%, respectively) were rare. The positive rates of antinuclear antibody (59% and 45%, respectively) were high, whereas the positive rates of rheumatoid factor (6% and 10%, respectively) were rare for both groups. There were no differences on peripheral blood counts between the two groups. However, γδT-LGLL patients were found to be predominantly expressed a CD4(-)/CD8(-) phenotype. Steroid therapy with prednisone was used alone as first-line therapy for 1 patient. Cyclosporin A (CsA) was used alone as first-line therapy for 3 patients. CsA in combination with steroids were administered in 13 patients. After 4 months treatment, 2 patients acquired complete response, 4 patients acquired partial response, the overall response was 35%. Conclusion: γδT-LGLL is a rare mature T-lymphocyte proliferative disease. Clinical and laboratory characteristics were quite similar for γδT-LGLL in compare with αβT-LGLL. γδT-LGLL predominantly expressed a CD4(-)/CD8(-) phenotype. The data presented here indicate the CsA is an effective option for the first-line treatment of γδT-LGLL.
- Open Access
- 15 May 2019
- Published by S. Karger AG in Acta Haematologica
- Vol. 142 (3) , 162-170
Current Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study
Aplastic anemia (AA) is a hematologic disease characterized by pancytopenia and hypocellular bone marrow, potentially leading to chronic anemia, hemorrhage, and infection. The China Aplastic Anemia Committee and British Committee for Standards in Haematology guidelines recommend hematopoietic stem-cell transplantation (HSCT) or immunosuppressive therapy (IST) comprising antithymocyte globulin (ATG) with cyclosporine (CsA) as initial treatment for AA patients. With limited epidemiological data on the clinical management of AA in Asia, a prospective cohort registry study involving 22 AA treatment centers in China was conducted to describe the disease characteristics of newly diagnosed AA patients and investigate real-world treatment patterns and patient outcomes. Of 340 AA patients, 72.9, 12.6, and 3.5% were receiving IST, traditional Chinese medicine, and HSCT, respectively, at baseline; only 22.2% of IST-treated patients received guideline-recommended ATG with CsA initially. Almost all patients received supportive care (95.6%) as blood transfusion (97.8%), antibiotics (63.7%), and/or hematopoietic growth factors (58.2%). Overall, 64.8% achieved a partial or complete response, and 0.9% experienced relapse. No new safety concerns were identified; serious adverse events were largely unrelated to the treatment regimen. These results demonstrate the need to identify and minimize treatment barriers to standardize and align AA management in China with treatment guideline recommendations and further improve patient outcomes.
- 15 May 2019
- Published by S. Karger AG in Acta Haematologica
- Vol. 142 (3) , 162-170
Open AccessCurrent Treatment Patterns of Aplastic Anemia in China: A Prospective Cohort Registry Study
Aplastic anemia (AA) is a hematologic disease characterized by pancytopenia and hypocellular bone marrow, potentially leading to chronic anemia, hemorrhage, and infection. The China Aplastic Anemia Committee and British Committee for Standards in Haematology guidelines recommend hematopoietic stem-cell transplantation (HSCT) or immunosuppressive therapy (IST) comprising antithymocyte globulin (ATG) with cyclosporine (CsA) as initial treatment for AA patients. With limited epidemiological data on the clinical management of AA in Asia, a prospective cohort registry study involving 22 AA treatment centers in China was conducted to describe the disease characteristics of newly diagnosed AA patients and investigate real-world treatment patterns and patient outcomes. Of 340 AA patients, 72.9, 12.6, and 3.5% were receiving IST, traditional Chinese medicine, and HSCT, respectively, at baseline; only 22.2% of IST-treated patients received guideline-recommended ATG with CsA initially. Almost all patients received supportive care (95.6%) as blood transfusion (97.8%), antibiotics (63.7%), and/or hematopoietic growth factors (58.2%). Overall, 64.8% achieved a partial or complete response, and 0.9% experienced relapse. No new safety concerns were identified; serious adverse events were largely unrelated to the treatment regimen. These results demonstrate the need to identify and minimize treatment barriers to standardize and align AA management in China with treatment guideline recommendations and further improve patient outcomes.
- 11 October 2018
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 24, 7256-7263
Iron Deficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Cross-Sectional Survey from a Single Institution in China
BACKGROUND:Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder that often manifests with chronic intravascular hemolysis. Iron deficiency in patients with PNH is most often due to urinary losses of iron secondary to...
- 11 October 2018
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 24, 7256-7263
Iron Deficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Cross-Sectional Survey from a Single Institution in China
BACKGROUND:Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder that often manifests with chronic intravascular hemolysis. Iron deficiency in patients with PNH is most often due to urinary losses of iron secondary to...
- 10 July 2018
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 40 (6) , 630-636
Evaluation on the genetic instability detecting methods for rapid diagnose of Fanconi anemia used in the undeveloped areas of China
Introduction: Fanconi anemia (FA), as one of the congenital bone marrow failure syndromes, is characterized by severe bone marrow hypocellularity and pancytopenia which is similar with acquired aplastic anemia (AAA). However, patients with FA or AAA need an accurate diagnose, as the two syndromes differ significantly in both treatment and prognosis. FA results from gene mutations of the FA pathway genes specifically required for DNA repair, and the mutation of these genes contributes to the genome instability of FA cells. Based on this feature, chromosome aberration (CA) has been used as a “golden standard” to the auxiliary diagnosis of FA from AAA. However, CA diagnose calls for more technical requirements and a long time for the subsequent statistical analysis.Methods: In our study, another two genome instability examination tools, cytokinesis‐block micronucleus (CBMN) and single‐cell gel electrophoresis (SCGE), were used to distinguish FA patients from AAA patients, compared with CA.Results: The results suggested that significant differences were observed in the FA patients compared with the AAA patients and the controls using all of the three genomic instability examination tools. However, CBMN is the most cost‐effective method to distinguish FA patients from AAA patients among the three genome instability examination tools, when the time costs, instrument costs, and technical costs were compared.Conclusion: In areas with economic and technical limitations, CBMN is an alternative assay to help distinguish FA patients from AAA patients.
- 10 July 2018
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 40 (6) , 630-636
Evaluation on the genetic instability detecting methods for rapid diagnose of Fanconi anemia used in the undeveloped areas of China
Introduction: Fanconi anemia (FA), as one of the congenital bone marrow failure syndromes, is characterized by severe bone marrow hypocellularity and pancytopenia which is similar with acquired aplastic anemia (AAA). However, patients with FA or AAA need an accurate diagnose, as the two syndromes differ significantly in both treatment and prognosis. FA results from gene mutations of the FA pathway genes specifically required for DNA repair, and the mutation of these genes contributes to the genome instability of FA cells. Based on this feature, chromosome aberration (CA) has been used as a “golden standard” to the auxiliary diagnosis of FA from AAA. However, CA diagnose calls for more technical requirements and a long time for the subsequent statistical analysis.Methods: In our study, another two genome instability examination tools, cytokinesis‐block micronucleus (CBMN) and single‐cell gel electrophoresis (SCGE), were used to distinguish FA patients from AAA patients, compared with CA.Results: The results suggested that significant differences were observed in the FA patients compared with the AAA patients and the controls using all of the three genomic instability examination tools. However, CBMN is the most cost‐effective method to distinguish FA patients from AAA patients among the three genome instability examination tools, when the time costs, instrument costs, and technical costs were compared.Conclusion: In areas with economic and technical limitations, CBMN is an alternative assay to help distinguish FA patients from AAA patients.
- 14 April 2015
- Published by Wiley in British Journal of Haematology
- Vol. 171 (4) , 647-649
A novel splicing mutation of TMPRSS6 in a Chinese child with iron‐refractory iron deficiency anaemia
- 14 April 2015
- Published by Wiley in British Journal of Haematology
- Vol. 171 (4) , 647-649
A novel splicing mutation of TMPRSS6 in a Chinese child with iron‐refractory iron deficiency anaemia
- 1 April 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (4) , 286-294
Rabbit antithymocyte globulin as first-line therapy for severe aplastic anemia
- 1 April 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (4) , 286-294
Rabbit antithymocyte globulin as first-line therapy for severe aplastic anemia
- Open Access
- 30 March 2015
- Published by Wiley in British Journal of Haematology
- Vol. 171 (3) , 427-430
Frontline therapy of severe aplastic anaemia with fludarabine, cyclophosphamide and ciclosporin
- 30 March 2015
- Published by Wiley in British Journal of Haematology
- Vol. 171 (3) , 427-430
Open AccessFrontline therapy of severe aplastic anaemia with fludarabine, cyclophosphamide and ciclosporin